A number of studies report that donor and recipient HLA-E*01:03 homozygous genotype is related with better HSCT outcome due to a lower risk of acute and chronic GvHD development and a lower rate of relapse (48–53). The gene discussed is HLA-E; the disease is graft versus host disease.